In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Health Systems Are Learning To Embrace AI As A Force For Good

AI Is Increasingly Seen As A Realistic Solution To The Demand Overload On Clinicians

Executive Summary

The term artificial intelligence was coined at the Dartmouth Summer Research Project in 1956, but it is only in very recent years that it has been consistently at the top of the agenda in discussions on the future direction of health care. As a tool to improve both the quality and speed of care, AI is now increasingly seen as a realistic solution to the demand overload on clinicians. At the same time, techno-fears are abating. This confluence will transform health care radically in the next two decades.

You may also be interested in...



Medtronic Unveils New AI Colonoscopy System, GI Genius

Medtronic has launched a new artificial intelligence enhanced endoscopy system, for recognizing pre-cancerous polyps, in Europe. The gastroenterology community convened at an expert panel discussion hosted by Medtronic during UEG Week to discuss the future of AI in endoscopy.

Medtech’s AI Pioneers – Where Are We Headed?

Artificial intelligence (AI) is quickly becoming part of our day-to-day routines, and healthcare is one area in which AI stands to make the biggest impact. But where is the technology headed? Leading figures from the medtech industry gathered at the Medical Design & Manufacturing East (MD&M East) meeting held in New York City to discuss.

A ‘Blood Pressure Test’ For Dementia

The attention accorded to dementia, MCI and degenerative brain conditions has been slow to reach the levels given to the more visibly-quantifiable conditions, such as cardiovascular disease and oncology. But earlier detection of cognitive impairment is a priority, despite therapies not yet being available to halt or reverse the conditions. Playing its part to push back the boundaries is Cognetivity Neurosciences, a London-based company with an innovative tool that uses AI to test subjects for the early signs of dementia.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV124393

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel